Product image of Mulfinya (Fingolimod) supplied by GNH India

Mulfinya

Active Ingredient:
Fingolimod
Origin:
EU

Mulfinya (Fingolimod)

Fingolimod, the active ingredient in Mulfinya, is a sphingosine 1‑phosphate receptor modulator presented as an oral tablet for oral use. It treats relapsing‑remitting multiple sclerosis in adult patients.

GNH India supplies Mulfinya as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Mylan Germany Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Mulfinya (fingolimod) is indicated as a disease‑modifying therapy within the multiple sclerosis treatment pathway.

  • Relapsing‑remitting multiple sclerosis: reduces the frequency of clinical relapses and slows disability progression.
  • Active disease in adults: decreases new inflammatory lesions detected on MRI.
  • High lesion activity: limits accumulation of new brain lesions over time.

How It Works

  • After oral absorption, fingolimod is phosphorylated to an active metabolite that binds to sphingosine‑1‑phosphate (S1P) receptors, particularly S1P1, on lymphocytes. This functional antagonism sequesters lymphocytes within lymph nodes, preventing their migration into the central nervous system and thereby reducing autoimmune inflammation associated with multiple sclerosis.

Side Effects

Fingolimod may cause a range of adverse reactions, which are grouped by frequency.

Common Side Effects

  • Headache: mild to moderate intensity.
  • Nasopharyngitis: upper respiratory tract infection symptoms.
  • Diarrhea: loose stools, usually transient.
  • Elevated liver enzymes: mild transaminase increase.
  • Fatigue: persistent tiredness.
  • Cough: dry or productive.

Serious or Rare Side Effects

  • Infections: opportunistic or severe bacterial infections.
  • Cardiac arrhythmia: bradycardia or conduction delays.
  • Macular edema: visual disturbances requiring ophthalmic evaluation.
  • Progressive multifocal leukoencephalopathy: rare viral brain infection.
  • Severe liver injury: marked transaminase elevation or hepatitis.
  • Malignancy: increased risk of certain cancers.

Precautions & Warnings

Before initiating Mulfinya, several safety considerations should be observed.

  • Pregnancy: contraindicated; avoid use during pregnancy.
  • Liver function: monitor transaminases before and during therapy.
  • Cardiac assessment: perform baseline ECG and monitor heart rate after first dose.
  • Ophthalmic monitoring: conduct regular eye exams to detect macular edema.
  • Live vaccines: avoid administration while on therapy.
  • Store at ambient temperature: keep in the original pack, protect from moisture.

Avoid Interactions

Fingolimod interacts with several drug classes; awareness of interaction severity guides clinical decisions.

Major Interactions (Avoid)

  • Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase fingolimod exposure.
  • Other S1P modulators: additive immunosuppression risk.
  • Live vaccines: heightened infection risk.

Moderate Interactions (Monitor Closely)

  • CYP3A4 inducers (e.g., rifampin): may reduce efficacy.
  • Beta‑blockers: may exacerbate bradycardia.
  • Antihypertensives: potential additive blood pressure effects.
  • Non‑live vaccines: monitor immune response.

Frequently Asked Questions

Mulfinya contains fingolimod, which is used as a disease‑modifying therapy for adults with relapsing‑remitting multiple sclerosis. It helps lower the rate of clinical relapses and slows the progression of disability associated with the disease.

Fingolimod is phosphorylated after oral intake and then binds to sphingosine‑1‑phosphate receptors on lymphocytes. This binding traps the lymphocytes in lymph nodes, reducing their ability to enter the central nervous system and thereby decreasing inflammatory damage in multiple sclerosis.

The specific dose of Mulfinya is determined by the prescribing clinician based on individual patient factors, regulatory guidelines, and therapeutic response. Patients should follow the dosage instructions provided by their healthcare professional.

Mulfinya is contraindicated in pregnancy because fetal exposure can cause serious harm. Women of childbearing potential should use effective contraception. Safety during breastfeeding has not been established, and breastfeeding is generally not recommended while on therapy.

To request Mulfinya, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and necessary import documentation.

Mulfinya (fingolimod) is an oral sphingosine‑1‑phosphate receptor modulator, offering a convenient once‑daily tablet compared with injectable disease‑modifying therapies. Its efficacy in reducing relapse rates is comparable to some injectables, but safety profiles differ, especially regarding cardiac and infection risks.

Mulfinya should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture. Keep the product away from direct sunlight and excessive heat to maintain stability.

Mulfinya is taken orally as a tablet, usually once daily, with or without food. Patients should swallow the tablet whole and not split, crush, or chew it unless otherwise instructed by a healthcare professional.

Serious risks include severe infections, cardiac arrhythmias such as bradycardia, macular edema leading to vision changes, progressive multifocal leukoencephalopathy, and significant liver injury. Patients should be monitored regularly for these complications.

Mulfinya should not be used by individuals who are pregnant, have uncontrolled cardiac conditions, active severe infections, significant liver disease, or who are receiving live vaccines. Contraindications are defined by the prescribing information and should be reviewed by a clinician.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Fingolimod

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT